Abrey Lauren E, Correa Denise D
Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Hematol Oncol Clin North Am. 2005 Aug;19(4):729-38, viii. doi: 10.1016/j.hoc.2005.05.010.
Two challenges need to be addressed to improve the outcome of patients with primary central nervous system lymphoma. The first challenge is to develop therapies that result in less toxicity and improved long-term outcome. The second challenge is to develop interventions to help those patients who develop treatment-related neurotoxicity; ongoing collaborative efforts are required to improve communication and understanding of this complication. Long-term follow up of prospective therapeutic studies should report on both disease control and the development of neurotoxicity. New protocols should include prospective longitudinal measures of neurocognitive function.
为改善原发性中枢神经系统淋巴瘤患者的治疗效果，需要应对两个挑战。第一个挑战是开发毒性更小、长期疗效更佳的治疗方法。第二个挑战是制定干预措施，以帮助那些出现治疗相关神经毒性的患者；需要持续的合作努力来加强对这种并发症的沟通和理解。前瞻性治疗研究的长期随访应报告疾病控制情况和神经毒性的发生情况。新的方案应包括神经认知功能的前瞻性纵向测量。
